Want to see DGX full AI Analyst Report?
DGX Stock Chart & Stats
$227.86
-$0.04(-0.02%)
At close: 4:00 PM EDT
$227.86
-$0.04(-0.02%)
Day’s Range― - ―
52-Week Range$166.75 - $240.13
Previous CloseN/A
Volume1.54M
Average Volume (3M)984.83K
Market Cap
$25.59B
Enterprise Value$29.88K
Total Cash (Recent Filing)$626.00M
Total Debt (Recent Filing)$6.38B
Price to Earnings (P/E)24.7
Beta0.04
Next Earnings
Oct 27, 2026EPS Estimate
2.87Next Dividend Ex-DateN/A
Dividend Yield1.41%
Share Statistics
EPS (TTM)9.54
Shares Outstanding110,373,360
10 Day Avg. Volume1,322,295
30 Day Avg. Volume984,831
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)2.69
Price to Sales (P/S)1.75
P/FCF Ratio14.17
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$252.70Price Target Upside10.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)11.07
Revenue Forecast (FY)$11.96B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Raised GuidanceManagement raised full‑year 2026 revenue guidance after Q2 organic revenue and volume strength, indicating durable end-market demand across physician, hospital and consumer channels. Sustained organic growth supports reinvestment in higher‑value tests and underpins medium‑term revenue visibility.
Strong Cash Generation And Solid Balance SheetQuest generates substantial operating and free cash flow in absolute terms and maintains a balanced capital structure. This cash generation funds capex, Project Nova, and strategic initiatives while the moderate leverage level preserves financial flexibility over the next several quarters.
Clinical/commercial Momentum And Product ApprovalsRegulatory approval plus EHR integration broadens commercial access to a high‑value oncology MRD test. That combination strengthens Quest's specialty testing portfolio and distribution channels, supporting durable revenue mix improvement and differentiation in advanced diagnostics.
Bears Say
Near-term Margin Pressure From Transformation And MixProject Nova implementation costs and large low‑reimbursement contract ramps are compressing operating margins. Because Nova spend is skewed to H2 and mix shifts reflect durable contractual flows, margin recovery may be delayed and operating leverage limited over the next several quarters.
Regulatory And Reimbursement UncertaintyIndustry reimbursement rules (PAMA data/rate updates) and ACA subsidy changes create structural revenue per‑test risk. Persistent reimbursement volatility can erode realized prices across routine and specialty tests and complicate multi‑quarter planning and margin sustainability.
Weaker Cash Conversion And Declining FCF GrowthReduced cash conversion and a recent decline in FCF limit internal funding capacity for M&A, buybacks or accelerated capex. If working capital or cash needs remain elevated, financial flexibility to absorb reimbursement or margin shocks will be constrained over the medium term.
Quest Diagnostics News
DGX FAQ
What was Quest Diagnostics’s price range in the past 12 months?
Quest Diagnostics lowest stock price was $166.75 and its highest was $240.13 in the past 12 months.
What is Quest Diagnostics’s market cap?
Quest Diagnostics’s market cap is $25.59B.
When is Quest Diagnostics’s upcoming earnings report date?
Quest Diagnostics’s upcoming earnings report date is Oct 27, 2026 which is in 89 days.
How were Quest Diagnostics’s earnings last quarter?
Quest Diagnostics released its earnings results on Jul 23, 2026. The company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.823 by $0.297.
Is Quest Diagnostics overvalued?
According to Wall Street analysts Quest Diagnostics’s price is currently Undervalued.
Does Quest Diagnostics pay dividends?
Quest Diagnostics pays a Quarterly dividend of $0.86 which represents an annual dividend yield of 1.41%. See more information on Quest Diagnostics dividends here
What is Quest Diagnostics’s EPS estimate?
Quest Diagnostics’s EPS estimate is 2.87.
How many shares outstanding does Quest Diagnostics have?
Quest Diagnostics has 110,373,360 shares outstanding.
What happened to Quest Diagnostics’s price movement after its last earnings report?
Quest Diagnostics reported an EPS of $3.12 in its last earnings report, beating expectations of $2.823. Following the earnings report the stock price went up 8.612%.
Which hedge fund is a major shareholder of Quest Diagnostics?
Currently, no hedge funds are holding shares in DGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quest Diagnostics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$252.70 (10.90% Upside)
$252.70 (10.90% Upside)
Blogger Sentiment
Bullish
DGX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 798.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.9%
Last 30 Days ▲ 15.4%
Last 30 Days ▲ 15.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.88%
12-Months-Change
Fundamentals
Return on Equity
1.41%
Trailing 12-Months
Asset Growth
6.07%
Trailing 12-Months
Company Description
Quest Diagnostics
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
DGX Company Deck
DGX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong operational and commercial momentum: double-digit revenue growth, robust volume expansion, notable diagnostic and commercial milestones (Haystack MRD approval, Flatiron integration), meaningful adjusted EPS growth (+19.1%) and a raised full-year guide. Offsetting these positives are short-term margin pressures (70 bps headwind in Q2 from Nova ramp, Corewell/Fresenius mix and deferred compensation), higher expected H2 costs (fuel and Nova), and regulatory reimbursement risk (PAMA uncertainty and a ~30 bps ACA headwind). On balance, the positives (top-line strength, EPS improvement, raised guidance, product/partnership milestones, and productivity/automation investments) significantly outweigh the headwinds.View all DGX earnings summariesDGX Revenue Breakdown
97.73% Diagnostic Information Services
2.27% DS businesses
DGX Stock 12 Month Forecast
Average Price Target
$252.70
▲(10.90% Upside)
Technical Analysis
Ownership Overview
0.46% Insiders
28.71% Mutual Funds
2.23% Other Institutional Investors
39.45% Public Companies and
Individual Investors